摘要
淋巴细胞特异性蛋白酪氨酸激酶(Lymphocyte-specific protein tyrosine kinase,Lck or p56Lck)是一种在T细胞和自然杀伤细胞中表达的Src家族的细胞质酪氨酸激酶。在T细胞活化中,Lck的激活是一个必要步骤,故选择性抑制Lck可以产生免疫抑制作用。此外,Lck激酶在其他细胞中的异位表达可以诱发细胞发生癌变,因此抑制Lck还能起到抗癌作用。本文综述了Lck激酶作用机理及近年来的Lck激酶抑制剂的最新进展。
The lymphocyte-specific kinase（Lck or p56Lck） was a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer cells.Activation of the Lck in T cell was a necessary step,and the selective inhibition of Lck can produce immunosuppression.In addition,ectopic expression of Lck in other cells can induce cells to become cancerous.Therefore,inhibition of expression of Lck can also prohibit cancer.Action mechanism of Lck and the latest progress of the Lck inhibitor in recent years were reviewed.
出处
《广州化工》
CAS
2012年第10期17-20,44,共5页
GuangZhou Chemical Industry
作者简介
顾亚洲，男，硕士研究生，主要从事抗肿瘤药物的合成。
通讯作者：陆涛，男，教授，博士生导师，主要从事抗肿瘤药物设计与开发。
